Integrated blood purification therapy for sepsis associated acute kidney injury: a multicenter, prospective cohort study

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2000038267

Enrollment

Unknown

Registered

2020-09-15

Start date

2020-09-20

Completion date

Unknown

Last updated

2020-12-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sepsis-associated Acute Kidney Injury

Interventions

routine treatment group, CVVH group and HBP (CVVH+HP) group:Nil

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients with sepsis associated acute kidney injury (sa-aki) admitted to ICU continuously during the study period. 1. The age of adult patients in ICU is more than 18 years old; 2. Patients meeting sepsis 3.0 diagnostic criteria and sa-aki criteria; 3. Patients with informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients allergic to resin, heparin or protamine; 2. Patients with previous chronic kidney disease (CKD); 3. Patients who have previously received renal replacement therapy (RRT); 4. Dying state; 5. Patients who gave up treatment during the study.

Design outcomes

Primary

Measure	Time frame
all-cause mortality of 30 days in SA-AKI patients;	—

Secondary

Measure	Time frame
all-cause mortality of 90 days in SA-AKI patients;Incidence of CKD in survivors within 90 days;	—

Countries

China

Contacts

Public ContactLi Wenxiong

Beijing Chaoyang Hospital Affiliated to Capital Medical University

lwx7115@sina.com+86 13601097813

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026